Sign In
Buy UBX
$0.200
+0 (+0%)
At Close: Oct 10, 2025
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
05:00pm, Tuesday, 14'th May 2024
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agin
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
08:00am, Thursday, 25'th Apr 2024
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse disease
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
08:00am, Tuesday, 23'rd Apr 2024
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
07:00am, Monday, 15'th Apr 2024
SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
08:00am, Tuesday, 12'th Dec 2023
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
04:05pm, Monday, 13'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
08:00am, Friday, 10'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
05:14pm, Tuesday, 17'th Oct 2023
Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
07:00am, Wednesday, 27'th Sep 2023
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
04:05pm, Tuesday, 08'th Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi
Unity (UNX) Down on Disappointing Results From Wet AMD Study
04:45pm, Tuesday, 28'th Mar 2023
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
12:00pm, Monday, 27'th Mar 2023
Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it'
Unity Biotechnology (UBX) Stock Pops on Positive Study Data
12:45pm, Tuesday, 01'st Nov 2022
Unity Biotechnology (NASDAQ: UBX ) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. UBX1325 is the company's treatment in development to treat p
Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results
08:15am, Monday, 24'th Oct 2022
A small cap biotech targeting diseases of ageing, with a lead compound focusing on ophthalmology that recently reported positive trial results. Not overly reliant on debt and has reported some revenue
